The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 04, 2023

Filed:

Sep. 24, 2019
Applicant:

International Business Machines Corporation, Armonk, NY (US);

Inventors:

Benjamin Goudey, Victoria, AU;

Annalisa Jean Swan, Victoria, AU;

Noel Garry Faux, Victoria, AU;

Roslyn Hickson, Victoria, AU;

Christine Schieber, Victoria, AU;

Bowen Fung, Pasadena, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
G16H 50/70 (2018.01); G16H 50/30 (2018.01); G06N 20/00 (2019.01); G16H 70/60 (2018.01); G16H 50/00 (2018.01); G06K 9/62 (2022.01); G06N 5/00 (2006.01);
U.S. Cl.
CPC ...
G16H 50/70 (2018.01); G06N 20/00 (2019.01); G16H 50/00 (2018.01); G16H 50/30 (2018.01); G16H 70/60 (2018.01);
Abstract

Method and apparatus for predicting amyloid beta (Aβ) and phosphorylated tau (p-tau) biomarker levels in the cerebrospinal fluid (CSF) of patients. Embodiments include determining current values for a plurality of easily-measurable attributes of a first patient. Embodiments include analyzing data associated with a cohort of patients having known measurements of Aβ and p-tau biomarker levels, including determined values for the plurality of easily-measureable attributes. Embodiments include generating a predicted value for Aβ and/or p-tau biomarker levels for the first patient. Embodiments include generating a risk of the first patient developing AD at a future time, generating a probability of a patient's predicted rate of decline, and/or generating a probability of a patient's age at the onset of dementia, based on the predicted values for Aβ and/or p-tau biomarker levels.


Find Patent Forward Citations

Loading…